2025 Partners
Exhibition Partners:
EuroscreenFast
Based in Charleroi, Belgium, EuroscreenFast has been a pioneer in GPCR science for more than 30 years, offering a catalogue of over 1,000 functional assays representing more than 530 GPCR and other targets. EuroscreenFast also boasts an impressive deorphanisation track record with the identification of 17 natural receptor-ligand pairs, as well as one of the largest libraries of orphan GPCR cell lines. Custom cell line and assay development is another core offering.
Furthermore, EuroscreenFast has developed specialized assays to bridge the gap between in vitro and in vivo data. Therapeutic developers worldwide know that EuroscreenFast strategically design each program based on the latest knowledge of the target’s biology – EuroscreenFast is your unrivalled GPCR development partner.
WuXi AppTec
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients.
Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."